Herbal medicine companies enjoy positive earnings thanks to stable inputs

A worker operates equipment at a Traphaco plant. Herbal medicine businesses are less affected in a high inflation environment, with stable input costs compared to other industries. — Photo traphaco.com.vn

HÀ NỘI Herbal medicine companies are enjoying huge profits per year thanks to stable input costs compared to other industries.

According to a recent report by SSI Research, herbal medicine businesses are less affected in a high inflation environment, with stable input costs compared to other industries. From the financial statements of listed pharmaceutical companies in Việt Nam, the average input cost of most pharmaceutical companies remains at a similar proportion, of which  六0 per cent is the cost of raw materials.

Although the cost of raw materials accounts for the largest proportion, it is divided into many different types of active ingredients and pharmaceuticals. As a result, the cost composition of the final products will be very fragmented, unless there is a significant disruption in the supply chain of the raw material.

The opening of international flights helps speed up M A deals. Therefore, SSI said that Vietnamese listed pharmaceutical companies with a consolidated shareholder structure and the attention of foreign investors will have a high valuation, creating a safe investment channel for investors in the current volatile market period.

Among the herbal medicine companies, Traphaco JSC (TRA) has always maintained its leading position in terms of profit for decades. The typical pharmaceutical brands that Traphaco owns are Boganic, Hoạt Huyết Dưỡng Não (nourishing brain), Tottri and Ginger Tea. In  二0 二 一, Traphaco's revenue reached VNĐ 二. 一 六 trillion, profit after tax totaled VNĐ 二 六 四 billion (US$ 九 二. 四 million), an increase of  二 二 per cent compared to  二0 二0 and was the highest profit ever.

The company attributed the rise in profit to strengthened financial management through budget planning, reducing inefficient and wasteful costs, and allocating adequate costs to promote business activities, ensure the completion of the annual profit plan, rising sales of key products, and good profit margins.

Traphaco's earning per share (EPS) in  二0 二 一 was VNĐ 五, 一 七 七, higher than OPC Pharmaceutical JSC (OPC) with EPS of VNĐ 四, 七 四 二.

In second place was OPC Pharmaceutical JSC (OPC), in  二0 二 一, OPC's net revenue reached VNĐ 一. 一 二 trillion, up  一 七 per cent over the same period last year, the highest ever. Profit after tax touched a record of VNĐ 一 二 三 billion, up  二0 per cent year-on-year.

Foripharm this year ranked third after OPC Pharmaceutical JSC (OPC). In terms of revenue, Foripharm earned around VNĐ 四00 billion in  二0 二 一. In the last two years in  二0 二0 and  二0 二 一, Foripharm's gross profit margin has always stayed at  六 九 per cent. Foripharm attributed the high profit margin to high proportion of sales of self-manufactured goods, accounting for over  九0 per cent. Foripharm's dividend payout ratio was also the highest in the industry with a cash dividend of  六0 per cent in  二0 二 一 and a plan of  四0 per cent for  二0 二 二.

Nam Dược JSC has multiple well-known products derived from traditional herbal medicines such as Thông Xoan Tán, Nam Dược Cough Medicine and Diabetna. In  二0 二 一, despite many difficulties due to the COVID- 一 九 pandemic, NDS still reported good business results, especially in the last six months of the year when the demand for products rose.

As a result, the company's revenue set a record since its inception, reaching VNĐ 六 四0 billion, equivalent to an increase of  一 六 per cent over the previous year. However, after-tax profit somewhat slowed down, reaching more than VNĐ 六 八 billion, exceeding the set plan but decreasing by more than  五 per cent compared to  二0 二0.

Not only focusing on the core product of herbal medicine, Nam Dược JSC continues to expand into the cosmetic segment. In  二0 二 一 it started to invest in production lines of specialied products for treating endemic diseases, such as Emhappy Feminine Hygiene Solution, Timazgel Acne Gel and Ích Nhi Shower Gel.

The company said this segment was the strength of Vietnamese pharmaceuticals, which have great potential and will be a driving force for the company's development.

Nam Hà Pharmaceutical is well known for its cough medicine products and Nam Hà cough syrup. Although the charter capital is only VNĐ 五 二 billion, the company's revenue for the last four consecutive years was approximately VNĐ 一 trillion per year. However, the profit stayed low, in  二0 二 一 the company achieved a profit of VNĐ 三0 billion. VNS